Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 26th at 6:00 PM EST.

To Purchase # 1525S

1525S 100 µg

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using IGF-I Receptor β Antibody #3027 in the presence of control peptide (left) or IGF-I Receptor β Blocking Peptide (right).

Learn more about how we get our images
Image

Product Description

This peptide is used to block IGF-I Receptor β Antibody #3027 reactivity in immunohistochemistry protocols.


Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks IGF-I Receptor β Antibody #3027 signal in immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocol. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.


Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

Insulin-like growth factor 1 (IGF-1) is a small (7.65 kDa) growth factor that interacts with both the IGF-1 receptor and the insulin receptor to control cell growth and apoptosis. Release of this endocrine hormone from the liver is stimulated by growth hormone produced in the anterior pituitary (1). Circulating IGF-1 is typically bound to one of six known IGF binding proteins (IGF-BP) (2). At target cells, the IGF-1 ligand binds IGF receptors (or insulin receptors) leading to receptor autophosphorylation and activation (3). Activated receptors mediate downstream signaling pathways (including Akt and MAPK) that regulate cell proliferation, apoptosis, development and longevity. Altered expression or mutation of IGF-1 is associated with several human disorders, including type I diabetes and various forms of cancer (4). Recombinant human IGF-1 has been used in clinical trials as a potential therapeutic agent in the treatment of human diseases (5).


1.  Le Roith, D. (1997) N Engl J Med 336, 633-40.

2.  Jones, J.I. and Clemmons, D.R. (1995) Endocr Rev 16, 3-34.

3.  Hernández-Sánchez, C. et al. (1995) J Biol Chem 270, 29176-81.

4.  Sandhu, M.S. (2005) Endocr Dev 9, 44-54.

5.  Trojan, J. et al. (2007) Neuroscience 145, 795-811.


Entrez-Gene Id 3480
Swiss-Prot Acc. P08069


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.